Nature Communications (Feb 2018)
Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL
- A. Schrader,
- G. Crispatzu,
- S. Oberbeck,
- P. Mayer,
- S. Pützer,
- J. von Jan,
- E. Vasyutina,
- K. Warner,
- N. Weit,
- N. Pflug,
- T. Braun,
- E. I. Andersson,
- B. Yadav,
- A. Riabinska,
- B. Maurer,
- M. S. Ventura Ferreira,
- F. Beier,
- J. Altmüller,
- M. Lanasa,
- C. D. Herling,
- T. Haferlach,
- S. Stilgenbauer,
- G. Hopfinger,
- M. Peifer,
- T. H. Brümmendorf,
- P. Nürnberg,
- K. S. J. Elenitoba-Johnson,
- S. Zha,
- M. Hallek,
- R. Moriggl,
- H. C. Reinhardt,
- M.-H. Stern,
- S. Mustjoki,
- S. Newrzela,
- P. Frommolt,
- M. Herling
Affiliations
- A. Schrader
- Department of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn, University of Cologne (UoC)
- G. Crispatzu
- Department of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn, University of Cologne (UoC)
- S. Oberbeck
- Department of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn, University of Cologne (UoC)
- P. Mayer
- Department of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn, University of Cologne (UoC)
- S. Pützer
- Department of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn, University of Cologne (UoC)
- J. von Jan
- Department of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn, University of Cologne (UoC)
- E. Vasyutina
- Department of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn, University of Cologne (UoC)
- K. Warner
- Department of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn, University of Cologne (UoC)
- N. Weit
- Department of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn, University of Cologne (UoC)
- N. Pflug
- Department of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn, University of Cologne (UoC)
- T. Braun
- Department of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn, University of Cologne (UoC)
- E. I. Andersson
- Hematology Research Unit Helsinki, Department of Medicine and Clinical Chemistry, University of Helsinki and Helsinki University Central Hospital (HUCH)
- B. Yadav
- Hematology Research Unit Helsinki, Department of Medicine and Clinical Chemistry, University of Helsinki and Helsinki University Central Hospital (HUCH)
- A. Riabinska
- Department of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn, University of Cologne (UoC)
- B. Maurer
- Institute of Animal Breeding and Genetics, University of Veterinary Medicine; Ludwig Boltzmann Institute for Cancer Research, Medical University of Vienna
- M. S. Ventura Ferreira
- Department of Hematology, Oncology, and Stem Cell Transplantation, RWTH Aachen University Medical School
- F. Beier
- Department of Hematology, Oncology, and Stem Cell Transplantation, RWTH Aachen University Medical School
- J. Altmüller
- Cologne Center for Genomics, UoC, Germany, Institute of Human Genetics, University of Cologne (UoC)
- M. Lanasa
- Duke University Medical Center
- C. D. Herling
- Department of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn, University of Cologne (UoC)
- T. Haferlach
- MLL Munich Leukemia Laboratory
- S. Stilgenbauer
- Department III of Internal Medicine, University Hospital Ulm
- G. Hopfinger
- Department of Internal Medicine, Bone Marrow Transplantation Unit, Medical University of Vienna
- M. Peifer
- Department of Translational Genomics, UoC
- T. H. Brümmendorf
- Department of Hematology, Oncology, and Stem Cell Transplantation, RWTH Aachen University Medical School
- P. Nürnberg
- Cologne Center for Genomics, UoC, Germany, Institute of Human Genetics, University of Cologne (UoC)
- K. S. J. Elenitoba-Johnson
- Department of Pathology and Laboratory Medicine, University of Pennsylvania, Perelman School of Medicine
- S. Zha
- Institute for Cancer Genetics, Department of Pathology and Cell Biology, Herbert Irving Comprehensive Cancer Center, Division of Pediatric Oncology, Department of Pediatrics, Columbia University Medical Center, Columbia University
- M. Hallek
- Department of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn, University of Cologne (UoC)
- R. Moriggl
- Institute of Animal Breeding and Genetics, University of Veterinary Medicine; Ludwig Boltzmann Institute for Cancer Research, Medical University of Vienna
- H. C. Reinhardt
- Department of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn, University of Cologne (UoC)
- M.-H. Stern
- INSERM U830, Institut Curie, PSL Research University
- S. Mustjoki
- Hematology Research Unit Helsinki, Department of Medicine and Clinical Chemistry, University of Helsinki and Helsinki University Central Hospital (HUCH)
- S. Newrzela
- Senckenberg Institute of Pathology, Goethe-University
- P. Frommolt
- Bioinformatics Core Facility, CECAD, UoC
- M. Herling
- Department of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn, University of Cologne (UoC)
- DOI
- https://doi.org/10.1038/s41467-017-02688-6
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 22
Abstract
T-cell prolymphocytic leukemia (T-PLL) is a rare malignancy with a poor prognosis. Here, the authors investigate the genomic landscape, gene expression profiles and functional mechanisms in 111 patients, highlighting TCL1 overexpression and ATM aberrations as core lesions which co-operate to impair DNA damage processing.
